Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Utilization of In Vitro, In Vivo and In Silico Tools to Evaluate the pH-Dependent Absorption of a BCS Class II Compound and Identify a pH-Effect Mitigating Strategy.

Gesenberg C, Mathias NR, Xu Y, Crison J, Savant I, Saari A, Good DJ, Hemenway JN, Narang AS, Schartman RR, Zheng N, Buzescu A, Patel J.

Pharm Res. 2019 Oct 21;36(12):164. doi: 10.1007/s11095-019-2698-0.

PMID:
31637544
2.

Elucidating Molecular- and Particle-Level Changes during the Annealing of a Micronized Crystalline Drug.

Puri V, Shur J, Narang AS.

Mol Pharm. 2019 Oct 7;16(10):4339-4351. doi: 10.1021/acs.molpharmaceut.9b00692. Epub 2019 Sep 9.

PMID:
31454254
3.

Correlations between surface composition and aerosolization of jet-milled dry powder inhaler formulations with pharmaceutical lubricants.

Mangal S, Park H, Nour R, Shetty N, Cavallaro A, Zemlyanov D, Thalberg K, Puri V, Nicholas M, Narang AS, Zhou QT.

Int J Pharm. 2019 Sep 10;568:118504. doi: 10.1016/j.ijpharm.2019.118504. Epub 2019 Jul 9.

PMID:
31299339
4.

Assessment of Biopharmaceutical Performance of Supersaturating Formulations of Carbamazepine in Rats Using Physiologically Based Pharmacokinetic Modeling.

Thakore SD, Thakur PS, Shete G, Gangwal R, Narang AS, Sangamwar AT, Bansal AK.

AAPS PharmSciTech. 2019 Apr 30;20(5):179. doi: 10.1208/s12249-019-1386-z.

PMID:
31041552
5.

Quantitative X-Ray Microcomputed Tomography Assessment of Internal Tablet Defects.

Yost E, Chalus P, Zhang S, Peter S, Narang AS.

J Pharm Sci. 2019 May;108(5):1818-1830. doi: 10.1016/j.xphs.2018.12.024. Epub 2019 Jan 10.

PMID:
30639743
6.

Cyclodextrin Reduces Intravenous Toxicity of a Model Compound.

Mantik P, Xie M, Wong H, La H, Steigerwalt RW, Devanaboyina U, Ganem G, Shih D, Flygare JA, Fairbrother WJ, Chakravarty P, Russell D, Fernandez GE, Narang AS.

J Pharm Sci. 2019 Jun;108(6):1934-1943. doi: 10.1016/j.xphs.2019.01.004. Epub 2019 Jan 11.

PMID:
30639736
7.

Crystal anisotropy explains structure-mechanics impact on tableting performance of flufenamic acid polymorphs.

Jain A, Shah HS, Johnson PR, Narang AS, Morris KR, Haware RV.

Eur J Pharm Biopharm. 2018 Nov;132:83-92. doi: 10.1016/j.ejpb.2018.09.006. Epub 2018 Sep 10.

PMID:
30213565
8.

Buffer exchange path influences the stability and viscosity upon storage of a high concentration protein.

Krause ME, Narang AS, Barker G, Herzer S, Deshmukh S, Lan W, Fichana D, Wasylyk JM, Demirdirek B, Zhang L, Fiske J, McGann M, Adams ML, Gandhi RB.

Eur J Pharm Biopharm. 2018 Oct;131:60-69. doi: 10.1016/j.ejpb.2018.07.014. Epub 2018 Jul 18.

PMID:
30031090
9.

Role of regional absorption and gastrointestinal motility on variability in oral absorption of a model drug.

Narang AS, Balakrishnan A, Morrison J, Li J, Wang J, Gu H, Taylor K, Santone K, Ehrmann J, Beyer S, Lu X, Ketner R, Pizzano J, Orcutt T, Shields E, Dulac H, Aborn S, Batchelder M, Lentz K.

Eur J Pharm Biopharm. 2017 Aug;117:333-345. doi: 10.1016/j.ejpb.2017.04.026. Epub 2017 Apr 25.

PMID:
28455207
10.

Application of In-line Focused Beam Reflectance Measurement to Brivanib Alaninate Wet Granulation Process to Enable Scale-up and Attribute-based Monitoring and Control Strategies.

Narang AS, Stevens T, Macias K, Paruchuri S, Gao Z, Badawy S.

J Pharm Sci. 2017 Jan;106(1):224-233. doi: 10.1016/j.xphs.2016.08.025. Epub 2016 Oct 19.

PMID:
27771049
11.

Resolution and Sensitivity of Inline Focused Beam Reflectance Measurement During Wet Granulation in Pharmaceutically Relevant Particle Size Ranges.

Narang AS, Stevens T, Hubert M, Paruchuri S, Macias K, Bindra D, Gao Z, Badawy S.

J Pharm Sci. 2016 Dec;105(12):3594-3602. doi: 10.1016/j.xphs.2016.09.001. Epub 2016 Oct 13.

PMID:
27745886
12.

Assessment of Tablet Surface Hardness by Laser Ablation and Its Correlation With the Erosion Tendency of Core Tablets.

Narang AS, Breckenridge L, Guo H, Wang J, Wolf AA, Desai D, Varia S, Badawy S.

J Pharm Sci. 2017 Jan;106(1):200-207. doi: 10.1016/j.xphs.2016.08.008. Epub 2016 Sep 26.

PMID:
27686683
13.

A Fluorescence-Based High-Throughput Coupled Enzymatic Assay for Quantitation of Isoaspartate in Proteins and Peptides.

Puri A, Quan Y, Narang AS, Adams M, Gandhi R, Nashine VC.

AAPS PharmSciTech. 2017 Apr;18(3):803-808. doi: 10.1208/s12249-016-0570-7. Epub 2016 Jun 24.

PMID:
27342117
14.

Process Analytical Technology for High Shear Wet Granulation: Wet Mass Consistency Reported by In-Line Drag Flow Force Sensor Is Consistent With Powder Rheology Measured by At-Line FT4 Powder Rheometer.

Narang AS, Sheverev V, Freeman T, Both D, Stepaniuk V, Delancy M, Millington-Smith D, Macias K, Subramanian G.

J Pharm Sci. 2016 Jan;105(1):182-7. doi: 10.1016/j.xphs.2015.11.030. Epub 2016 Jan 13.

PMID:
26852853
15.

Integrated Application of Quality-by-Design Principles to Drug Product Development: A Case Study of Brivanib Alaninate Film-Coated Tablets.

Badawy SI, Narang AS, LaMarche KR, Subramanian GA, Varia SA, Lin J, Stevens T, Shah PA.

J Pharm Sci. 2016 Jan;105(1):168-81. doi: 10.1016/j.xphs.2015.11.023. Epub 2016 Jan 13.

PMID:
26852852
16.

Reduced Maternal Erythrocyte Long Chain Polyunsaturated Fatty Acids Exist in Early Pregnancy in Preeclampsia.

Wadhwani NS, Narang AS, Mehendale SS, Wagh GN, Gupte SA, Joshi SR.

Lipids. 2016 Jan;51(1):85-94. doi: 10.1007/s11745-015-4098-5. Epub 2015 Dec 1.

PMID:
26626477
17.

Measuring the sticking of mefenamic acid powders on stainless steel surface.

Wang Z, Shah UV, Olusanmi D, Narang AS, Hussain MA, Gamble JF, Tobyn MJ, Heng JY.

Int J Pharm. 2015 Dec 30;496(2):407-13. doi: 10.1016/j.ijpharm.2015.09.067. Epub 2015 Oct 9.

18.

Effect of milling temperatures on surface area, surface energy and cohesion of pharmaceutical powders.

Shah UV, Wang Z, Olusanmi D, Narang AS, Hussain MA, Tobyn MJ, Heng JYY.

Int J Pharm. 2015 Nov 10;495(1):234-240. doi: 10.1016/j.ijpharm.2015.08.061. Epub 2015 Aug 24.

19.

Evaluating scale-up rules of a high-shear wet granulation process.

Tao J, Pandey P, Bindra DS, Gao JZ, Narang AS.

J Pharm Sci. 2015 Jul;104(7):2323-33. doi: 10.1002/jps.24504. Epub 2015 May 25.

PMID:
26010137
20.

Role of Self-Association and Supersaturation in Oral Absorption of a Poorly Soluble Weakly Basic Drug.

Narang AS, Badawy S, Ye Q, Patel D, Vincent M, Raghavan K, Huang Y, Yamniuk A, Vig B, Crison J, Derbin G, Xu Y, Ramirez A, Galella M, Rinaldi FA.

Pharm Res. 2015 Aug;32(8):2579-94. doi: 10.1007/s11095-015-1645-y. Epub 2015 Feb 28.

PMID:
25724158
21.

Real-time assessment of granule densification in high shear wet granulation and application to scale-up of a placebo and a brivanib alaninate formulation.

Narang AS, Sheverev VA, Stepaniuk V, Badawy S, Stevens T, Macias K, Wolf A, Pandey P, Bindra D, Varia S.

J Pharm Sci. 2015 Mar;104(3):1019-34. doi: 10.1002/jps.24233. Epub 2014 Dec 2.

PMID:
25470221
22.

Decoupling the contribution of dispersive and acid-base components of surface energy on the cohesion of pharmaceutical powders.

Shah UV, Olusanmi D, Narang AS, Hussain MA, Tobyn MJ, Heng JY.

Int J Pharm. 2014 Nov 20;475(1-2):592-6. doi: 10.1016/j.ijpharm.2014.09.018. Epub 2014 Sep 16.

23.

Decoupling the contribution of surface energy and surface area on the cohesion of pharmaceutical powders.

Shah UV, Olusanmi D, Narang AS, Hussain MA, Tobyn MJ, Hinder SJ, Heng JY.

Pharm Res. 2015 Jan;32(1):248-59. doi: 10.1007/s11095-014-1459-3. Epub 2014 Jul 19.

24.

Effect of crystal habits on the surface energy and cohesion of crystalline powders.

Shah UV, Olusanmi D, Narang AS, Hussain MA, Gamble JF, Tobyn MJ, Heng JY.

Int J Pharm. 2014 Sep 10;472(1-2):140-7. doi: 10.1016/j.ijpharm.2014.06.014. Epub 2014 Jun 10.

25.

Quality by design development of brivanib alaninate tablets: degradant and moisture control strategy.

Badawy SI, Lin J, Gokhale M, Desai S, Nesarikar VV, LaMarche KR, Subramanian GA, Narang AS.

Int J Pharm. 2014 Jul 20;469(1):111-20. doi: 10.1016/j.ijpharm.2014.04.059. Epub 2014 Apr 26.

PMID:
24780101
26.

Pharmaceutical development and regulatory considerations for nanoparticles and nanoparticulate drug delivery systems.

Narang AS, Chang RK, Hussain MA.

J Pharm Sci. 2013 Nov;102(11):3867-82. doi: 10.1002/jps.23691. Epub 2013 Aug 23.

PMID:
24037829
27.

Molecular basis of crystal morphology-dependent adhesion behavior of mefenamic acid during tableting.

Waknis V, Chu E, Schlam R, Sidorenko A, Badawy S, Yin S, Narang AS.

Pharm Res. 2014 Jan;31(1):160-72. doi: 10.1007/s11095-013-1149-6. Epub 2013 Aug 14.

PMID:
23943544
28.

Mechanistic basis for the effects of process parameters on quality attributes in high shear wet granulation.

Badawy SI, Narang AS, LaMarche K, Subramanian G, Varia SA.

Int J Pharm. 2012 Dec 15;439(1-2):324-33. doi: 10.1016/j.ijpharm.2012.09.011. Epub 2012 Sep 12.

PMID:
22981985
29.

Physicochemical interactions in solid dosage forms.

Narang AS, Desai D, Badawy S.

Pharm Res. 2012 Oct;29(10):2635-8. doi: 10.1007/s11095-012-0867-5. Epub 2012 Aug 31.

PMID:
22936283
30.

Impact of excipient interactions on solid dosage form stability.

Narang AS, Desai D, Badawy S.

Pharm Res. 2012 Oct;29(10):2660-83. doi: 10.1007/s11095-012-0782-9. Epub 2012 Jun 16. Review.

PMID:
22707362
31.

Formation of reactive impurities in aqueous and neat polyethylene glycol 400 and effects of antioxidants and oxidation inducers.

Hemenway JN, Carvalho TC, Rao VM, Wu Y, Levons JK, Narang AS, Paruchuri SR, Stamato HJ, Varia SA.

J Pharm Sci. 2012 Sep;101(9):3305-18. doi: 10.1002/jps.23198. Epub 2012 May 18.

PMID:
22610374
32.

Impact of excipient interactions on drug bioavailability from solid dosage forms.

Panakanti R, Narang AS.

Pharm Res. 2012 Oct;29(10):2639-59. doi: 10.1007/s11095-012-0767-8. Epub 2012 May 19. Review.

PMID:
22610283
33.

Reversible and pH-dependent weak drug-excipient binding does not affect oral bioavailability of high dose drugs.

Narang AS, Yamniuk AP, Zhang L, Comezoglu SN, Bindra DS, Varia S, Doyle ML, Badawy S.

J Pharm Pharmacol. 2012 Apr;64(4):553-65. doi: 10.1111/j.2042-7158.2011.01435.x. Epub 2012 Jan 13.

PMID:
22420661
34.

Effect of antioxidants and silicates on peroxides in povidone.

Narang AS, Rao VM, Desai DS.

J Pharm Sci. 2012 Jan;101(1):127-39. doi: 10.1002/jps.22729. Epub 2011 Aug 23.

PMID:
22109686
35.

Subcellular fate and off-target effects of siRNA, shRNA, and miRNA.

Singh S, Narang AS, Mahato RI.

Pharm Res. 2011 Dec;28(12):2996-3015. doi: 10.1007/s11095-011-0608-1. Epub 2011 Oct 28. Review.

PMID:
22033880
36.

Reactive impurities in excipients: profiling, identification and mitigation of drug-excipient incompatibility.

Wu Y, Levons J, Narang AS, Raghavan K, Rao VM.

AAPS PharmSciTech. 2011 Dec;12(4):1248-63. doi: 10.1208/s12249-011-9677-z. Epub 2011 Sep 27. Review.

37.

Role of tumor vascular architecture in drug delivery.

Narang AS, Varia S.

Adv Drug Deliv Rev. 2011 Jul 18;63(8):640-58. doi: 10.1016/j.addr.2011.04.002. Epub 2011 Apr 14. Review.

PMID:
21514334
38.

Effect of force feeder on tablet strength during compression.

Narang AS, Rao VM, Guo H, Lu J, Desai DS.

Int J Pharm. 2010 Nov 30;401(1-2):7-15. doi: 10.1016/j.ijpharm.2010.08.027. Epub 2010 Sep 9.

PMID:
20816733
39.

Stable drug encapsulation in micelles and microemulsions.

Narang AS, Delmarre D, Gao D.

Int J Pharm. 2007 Dec 10;345(1-2):9-25. Epub 2007 Sep 8. Review.

PMID:
17945446
40.

Co-expression of vascular endothelial growth factor and interleukin-1 receptor antagonist improves human islet survival and function.

Narang AS, Sabek O, Gaber AO, Mahato RI.

Pharm Res. 2006 Sep;23(9):1970-82. Epub 2006 Aug 12.

PMID:
16906455
41.

Biological and biomaterial approaches for improved islet transplantation.

Narang AS, Mahato RI.

Pharmacol Rev. 2006 Jun;58(2):194-243. Review.

PMID:
16714486
42.

Cationic lipids with increased DNA binding affinity for nonviral gene transfer in dividing and nondividing cells.

Narang AS, Thoma L, Miller DD, Mahato RI.

Bioconjug Chem. 2005 Jan-Feb;16(1):156-68.

PMID:
15656587
43.

Posttraumatic pseudotumor cerebri in a 4-year-old female.

Nelson K, Ward K, Narang AS.

Pediatr Emerg Care. 2004 Jul;20(7):460-3. No abstract available.

PMID:
15232248
44.

Vascular endothelial growth factor gene delivery for revascularization in transplanted human islets.

Narang AS, Cheng K, Henry J, Zhang C, Sabek O, Fraga D, Kotb M, Gaber AO, Mahato RI.

Pharm Res. 2004 Jan;21(1):15-25.

PMID:
14984253
45.

Emerging trends in oral delivery of peptide and protein drugs.

Mahato RI, Narang AS, Thoma L, Miller DD.

Crit Rev Ther Drug Carrier Syst. 2003;20(2-3):153-214. Review.

PMID:
14584523
46.

The emerging role of pediatric hospitalists.

Narang AS, Ey J.

Clin Pediatr (Phila). 2003 May;42(4):295-7. No abstract available.

PMID:
12800724
47.

Cationic lipid and polymer-based gene delivery to human pancreatic islets.

Mahato RI, Henry J, Narang AS, Sabek O, Fraga D, Kotb M, Gaber AO.

Mol Ther. 2003 Jan;7(1):89-100.

48.

Novel branched poly(ethylenimine)-cholesterol water-soluble lipopolymers for gene delivery.

Wang DA, Narang AS, Kotb M, Gaber AO, Miller DD, Kim SW, Mahato RI.

Biomacromolecules. 2002 Nov-Dec;3(6):1197-207.

PMID:
12425656
49.

Evaluation of solid dispersions of Clofazimine.

Narang AS, Srivastava AK.

Drug Dev Ind Pharm. 2002 Sep;28(8):1001-13.

PMID:
12378955
50.

A 7-year-old with tachycardia and widened pulse pressure.

Narang AS, English R, Knoebel EE, Ey J.

Clin Pediatr (Phila). 2002 Apr;41(3):141-4. No abstract available.

PMID:
11999676

Supplemental Content

Loading ...
Support Center